For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - BMI: 18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening - Must agree to follow specific methods of contraception, if applicable Healthy Participants (Part A and Part B) - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations - Males and Females, ages 18, or local age of majority, to 50 years, inclusive at screening Participants with Sjögren's Syndrome (Part C) - Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic condition based on the 2016 American College of Rheumatology-European League Against Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS) - Seropositive for anti-Sjögren's syndrome antigen A antibody - Males and females, ages 18, or local age of majority, to 65 years, inclusive at screening Exclusion Criteria: - Woman who are pregnant or breastfeeding - Inability to tolerate venipuncture and/or inadequate venous access Healthy Participants (Part A and Part B) - Any significant acute or chronic medical illness - Any other significant medical, psychiatric, and/or social reason as determined by the investigator Participants with Sjögren's Syndrome (Part C) - Systemic immune-mediated disease other than pSS, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease, or systemic sclerosis, that can better explain the majority of the symptoms (i.e., secondary Sjögren's syndrome) - Another immune-mediated disease or inflammatory condition that could interfere with assessment of response of pSS to therapy (e.g., immunoglobulin G4 (IgG4)-related disease, systemic sclerosis, inflammatory bowel disease, gout) - Any other medical condition associated with sicca syndrome (e.g., history of head and neck radiation treatment, diabetes mellitus, sarcoidosis, chronic graft-versus host disease), participants with sicca symptoms secondary to ongoing medication use based on the investigator's assessment Other protocol-defined inclusion/exclusion criteria apply